(GPAT) GP-Act III Acquisition - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: (N/A)
GPAT EPS (Earnings per Share)
GPAT Revenue
GPAT: Mergers, Acquisitions, Business Combinations
GP-Act III Acquisition Corp. is a special purpose acquisition company (SPAC) that aims to merge with or acquire a business, facilitating its entry into the public market. As a SPAC, it provides a unique opportunity for investors to participate in the growth of a company that has not yet been identified. With its base in New York, the company was initially known as GP Investments Acquisition Corp. II before rebranding in November 2020.
The companys strategy involves identifying a suitable target for a business combination, leveraging its expertise and resources to facilitate a successful merger or acquisition. As a blank-check company, GP-Act III Acquisition Corp.s success hinges on its ability to identify and capitalize on a promising investment opportunity, ultimately generating returns for its shareholders.
Analyzing the technical data, we observe that the stock has been exhibiting a relatively stable trend, with the short-term and long-term moving averages converging. The Average True Range (ATR) indicates low volatility, suggesting a period of consolidation. Based on the
From a fundamental perspective, the companys market capitalization stands at $374.47 million, with a price-to-earnings ratio of 30.65. The return on equity is 4.14%, indicating a relatively modest level of profitability. By combining the
However, if the company fails to identify a suitable target or complete a business combination within the allotted timeframe, the stock price may experience a decline, potentially falling to $9.50 or lower. As such, investors should closely monitor the companys progress and adjust their strategies accordingly.
Additional Sources for GPAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
GPAT Stock Overview
Market Cap in USD | 380m |
Sector | Financial Services |
Industry | Shell Companies |
GiC Sub-Industry | Diversified Financial Services |
IPO / Inception | 2024-07-01 |
GPAT Stock Ratings
Growth Rating | 47.4 |
Fundamental | 8.74 |
Dividend Rating | 0.0 |
Rel. Strength | -12.6 |
Analysts | - |
Fair Price Momentum | 10.01 USD |
Fair Price DCF | - |
GPAT Dividends
Currently no dividends paidGPAT Growth Ratios
Growth Correlation 3m | 97.5% |
Growth Correlation 12m | 98.7% |
Growth Correlation 5y | 98.7% |
CAGR 5y | 6.01% |
CAGR/Max DD 5y | 8.82 |
Sharpe Ratio 12m | -1.61 |
Alpha | 1.72 |
Beta | 0.012 |
Volatility | 3.97% |
Current Volume | 6.6k |
Average Volume 20d | 6.1k |
As of June 16, 2025, the stock is trading at USD 10.59 with a total of 6,648 shares traded.
Over the past week, the price has changed by +0.28%, over one month by +0.95%, over three months by +3.12% and over the past year by +6.01%.
Neither. Based on ValueRay´s Fundamental Analyses, GP-Act III Acquisition is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 8.74 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GPAT is around 10.01 USD . This means that GPAT is currently overvalued and has a potential downside of -5.48%.
GP-Act III Acquisition has no consensus analysts rating.
According to our own proprietary Forecast Model, GPAT GP-Act III Acquisition will be worth about 10.8 in June 2026. The stock is currently trading at 10.59. This means that the stock has a potential upside of +2.08%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 10.8 | 2.1% |